Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

pulation.

Other Preclinical Programs:

-- Preclinical data presented at the 5th Annual International

Anti-Angiogenesis Conference confirmed that Peregrine's fully human,

selective anti-VEGF antibody R84 was as effective as Avastin(R) in

inhibiting tumor growth in a model of human breast cancer. Selective

anti-VEGF agents may have potential advantages over non-selective

approaches.

Avid Bioservices:

-- Wholly owned manufacturing subsidiary Avid Bioservices signed an

agreement with ARIUS Research to produce clinical supplies of their

lead cancer stem cell anti-CD44 antibody.

-- Avid continued to demonstrate strong revenue performance during the

third quarter of fiscal year 2008.

Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infec
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Calif., September 22, 2014 Patients who were treated with ... hemorrhagic stroke were significantly more likely to survive than ... today in JAMA Neurology . This study was ... the use of cholesterol-lowering statins can improve survival in ... a constriction or obstruction of a blood vessel that ...
(Date:9/22/2014)... Boston, MA (PRWEB) September 22, 2014 ... major scientific breakthrough in drought tolerant grass seed this ... generation grass seed. The announcement coincides with the fact ... in the Spring as many believe. , As ... 300 rave and favorable reviews by industry experts and ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... VRML ) announced that on February 22, 2008 it ... indicated the Company is not in,compliance with Marketplace Rule ... $2,500,000 in stockholders, equity; (ii) $35,000,000 in market,value of ... continuing,operations for the most recently completed fiscal year or ...
... SAN DIEGO, Feb. 27 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter,and full year ended December 31, 2007., Total ... million,compared to $4.7 million in the fourth quarter of ... 2007 were $19.3 million, compared to $30.6,million in the ...
... Feb. 27 DARA BioSciences(TM),(Nasdaq: DARA ) announced ... Board of Directors. Mr. Cochrane was appointed to fill ... and Compensation Committees.,The appointment was effective February 21, 2008., ... Franco, Sr.,commented, "We are pleased that Haywood has joined ...
Cached Biology Technology:Vermillion Receives NASDAQ Notice of Non-Compliance 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 8Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 9Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 10Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 11DARA BioSciences, Inc. Announces Appointment of New Director to Board 2
(Date:9/22/2014)... Fla. --- Many native species have vanished from ... of Florida scientists have discovered how fossils can ... The key lies in organic materials found in ... ecosystems functioned, according to a new study available ... Journal of Herpetology . Pre-human island ecosystems ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... The smell of cut grass in recent years has ... but new research says the aroma also summons beneficial ... for protection, the plant signals the environment via the ... a feeding queue for parasitic wasps to come to ... in the pest insect," said Dr. Michael Kolomiets, Texas ...
Breaking Biology News(10 mins):Answer to restoring lost island biodiversity found in fossils 2Reversing the effects of pulmonary fibrosis 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... BLOOMINGTON, Ind. -- Extra genomes appear, on average, to offer ... key role in the origin of new species, say scientists ... week,s Proceedings of the National Academy of Sciences . ... acquisition of extra chromosome sets -- was a gateway to ...
... On Monday, August 17th at 1:30PM in Hensill Hall ... the AAAS in San Francisco will get to learn about ... brightest minds in the field. The symposium is called ... to the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As ...
... Researchers at Oregon State University have discovered that the ... them far more susceptible to pesticides at some times of ... scientists said, it may be possible to tap into this ... most vulnerable to a specific pesticide, and use that information ...
Cached Biology News:Genome duplication responsible for more plant species than previously thought 2Genome duplication responsible for more plant species than previously thought 3Science communication to take the stage at annual AAAS meeting in San Francisco 2Biological clocks of insects could lead to more effective pest control 2Biological clocks of insects could lead to more effective pest control 3
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Biology Products: